-->

Tag: retifanlimab-dlwr

Home / retifanlimab-dlwr

Categories

Retifanlimab-dlwr with carboplatin and paclitaxel is approved by the USFDA and as a single agent for squamous cell carcinoma of the anal canal

On May 15, 2025, the Food and Drug Administration sanctioned retifanlimab-dlwr (Zynyz, Incyte Corporation) in conjunction with carboplatin and paclitaxel for the initial treatment of people with inope...
retifanlimab-dlwr

Scan the code